The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback